NEW YORK (GenomeWeb News) – Genomic cancer test provider BioTheranostics today announced a contract with preferred provider network Prime Health Services for coverage of BioTheranostics' tests for breast cancer and metastatic disease.

Members of Prime Health now have access to San Diego-based BioTheranostics' molecular-based tests, including the Breast Cancer Index, which quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer, and CancerType ID for diagnosing metastatic cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.